Kết quả điều trị Gefitinib bước một ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn tiến xa có đột biến gen EGFR tại Bệnh viện Quân Y 103

To evaluate the efficacy of gefitinib as a first-line therapy in advanced-stage non-small cell lung cancer (NSCLC) patients with EGFR mutation who are non-smokers. Subjects and methods: A cross-sectional descriptive study on 32 patients with EGFR mutation-positive NSCLC who were non-smokers, treated with gefitinib as first-line therapy. Patients were monitored and evaluated for response every 3 months or when symptoms of disease progression occurred. Results: The disease control rate was 93.8%, with an overall response rate of 68.8%. The median progression-free survival time was 12.0 months. Progression-free survival rates at 3 months was 93.8%, at 6 months was 77.6%, and at 1 year was 39.6%. There was no statistically significant difference in progression-free survival time according to age, performance status, or EGFR mutation site (p > 0,05). Female patients had longer progression-free survival than male patients (p = 0.047). Conclusions: First-line gefitinib for advanced-stage NSCLC with EGFR mutation in the subgroup of non-smokers is highly effective, especially in female patients, and less adverse events.